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ABSTRACT
Psoriasis is an autoimmune disease and further classed as a chronic inflammatory skin condition serving as a global burden. A moderate to severe 
psoriasis can be treated with conventional therapies. Less efficacy, poor patient compliance, and toxicity issues were the major problems associated 
with conventional therapies. The introduction of biologic therapy has a great impression on psoriatic treatment duration and enhanced quality of life 
in psoriasis patients. The new biologic therapies are tailor-made medications with the goal of more specific and effective treatment; less toxicity. The 
biologic therapy is aimed to target antigen presentation and co-stimulation, T-cell activation, and leukocyte adhesion; and pro-inflammatory cascade. 
They act as effective and safer substitute to traditional therapy. Secukinumab, certolizumab, itolizumab, golimumab, ustekinumab, adalimumab, 
infliximab etanercept, alefacept, etc. are the approved biologic with the global market. This review briefs about psoriasis pathogenesis, traditional 
treatments, and biologic therapies potential.
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INTRODUCTION
Psoriasis is an autoimmune disease and further classed as a chronic 
inflammatory skin condition with prevalence ranging 1-3% in the 
world [1]. The five types of psoriasis are plaque psoriasis (psoriasis 
vulgaris), guttate, inverse psoriasis (intertriginous psoriasis), pustular, 
and erythrodermic. The most common is chronic plaque psoriasis [2]. 
This disease is characterized clinically by red-colored plaques with a 
silvery scale. It may affect all parts of skin but most commonly seen 
on the skin trunk, elbow, knees, scalps, in the finger nails and toe 
nails. Genetic, immunologic and environmental factors are playing an 
important role in the pathogenesis of psoriasis [3].
PATHOGENESIS OF PSORIASIS
The pathogenesis of psoriasis is complex and includes mediators of the 
innate immunity (especially dendritic cells [DCs] and keratinocytes) 
and adaptive immunity (T-lymphocytes). T-cells (T helper 17 [Th17] 
and Th1 cells) are mainly involved in the immunopathogenesis of 
psoriasis [4]. DCs are important constituent of the innate immune 
system, which are located in the epidermis as Langerhan cells and 
in the dermis as myeloid and plasmacytoid cells. The activation of 
antigen presenting cells (APCs) may be initiated due to stress, infection, 
medication, trauma, or unknown trigger. Antigen processing starts after 
activation of APCs. APCs are migrated to the regional lymph node where 
antigen is presented to T-lymphocytes [1].
The activation of T-cell by APC requires the presence of primary signal 
and presentation of antigen via the major histocompatibility complex 
on the APC to the T-cell receptor and a variety of co-stimulatory 
interactions. This process involves linkage of LFA-1, CD3, CD4/
CD8, CD2, CD40L, and CD28 on the surface of the T-lymphocyte with 
intracellular adhesion molecule-1 (ICAM-1), LFA-3, CD40, and B7 on the 
surface of the antigen-presenting cell [5].
The signaling between T-cell (CD28 glycoprotein) and APC (CD80/CD86 
glycoprotein) initiates transcription of wide range of cytokines, which 
are produced in the local microenvironment includes interleukin-1 
(IL-1), IL-2, IL-6, IL-12, interferon gamma (IFN-γ), tumor necrosis 
factor-alpha (TNF-α), and granulocyte-macrophage colony-stimulating 
factor [6]. These cytokines are important mediators of T-cell activation 
in psoriasis. The effects of these cytokine include keratinocyte 
migration, potentiation of Th1 type of response, angiogenesis, and 
epidermal hyperplasia [7].
TNF-α is plays vital role in the pathogenesis of psoriasis. It acts by 
promoting the release of various chemokine as well as inflammatory 
processes via expression of ICAM-1 and vascular adhesion protein-1 in 
keratinocytes and endothelial cells. This led to increased proliferation of 
keratinocytes and endothelial cells, resulting in epidermal hyperplasia 
and the formation of neocapillaries [6].
In psoriasis, presence of Th1 cytokines (IFN-γ, TNF-α and IL-12) 
in the dermis and epidermis induces proliferation and disordered 
maturation of keratinocytes, as well as the vascular changes were 
observed [8].
In addition, keratinocytes and DCs produce a higher level of IL-23, 
which stimulates Th17 cell production of IL-6, IL-17A, IL-17F, 
IL-21, and IL-22 in the dermis [9]. IL-22 predominantly stimulates 
keratinocyte hyperproliferation and epidermal acanthosis and 
hyperparakeratosis [10].
All these inflammatory responses and tissue changes finally lead to a 
condition of psoriasis (Fig. 1).
SEVERITY OF PSORIASIS
The severity of psoriasis is measured as mild, moderate, and severe 
depending on body surface area affected [2].
Mild psoriasis
Affects up to 3% of the body, generally in isolated patches on the knees, 
elbows, scalp, hands, and feet. It can often be controlled with topical 
therapy.
Moderate psoriasis
Affects 3-10% of the body’s surface. It often appears on the arms, legs, 
torso, scalp, and other areas. Topical agents, phototherapy, systemic 
medications, including biologics, may be appropriate.
Severe psoriasis
Affects >10% of the body. It may be extensive with plaques, pustules or 
erythroderma. Phototherapy, systemic medications, including biologics 
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or combination of these, with or without topical agents are usually 
necessary to achieve adequate results [11].
Etiology
The etiology of psoriasis is not known completely. It is associated with a 
complex interaction of genetic, environmental factors and other factors.
Genetic factor
Psoriasis belongs to the class of complex autoimmune genetic diseases 
that include diabetes, rheumatoid arthritis (RA), multiple sclerosis and 
Crohn’s disease [12].
Environmental factors
Environmental factors such as trauma, stress, infection (e.g., beta-
hemolytic streptococcal infection, staphylococcal, human 
immunodeficiency virus), and drugs (e.g., lithium, beta-blockers, 
non-steroidal anti-inflammatory drugs) can stimulate an extravagant 
immune-mediated response in the skin of genetically-susceptible 
individuals. This process eventually leads to hyperproliferation and 
inflammation of epidermal cells which is characteristic of psoriasis [6].
Hot weather and sunlight may be beneficial for psoriasis. Heller et al. 
said that proportion of psoriasis patients who believe stress affects 
their skin condition (i.e., “stress responders”) is considerably high, 
ranging from 37% to 78%. Stress may worsen psoriasis severity and 
may even lengthen the time to disease clearance [13].
Smoking
In one of a cross-sectional study of 338 patients, study findings revealed 
that the severity of psoriasis was more among smokers than among 
non-smokers. In this study, author correlated increased severity of 
psoriasis to nicotine dependence [14].
Immunologic factors
Recent advances in genetics and immunology have demonstrated the 
immune pathways relevant to psoriasis pathogenesis. Psoriasis lesions 
show high levels of dermal and circulating TNF-α, hence treatment with 
TNF-α inhibitors is often useful in psoriasis.
Psoriasis is a common dermatological disorder in India. In India, the 
prevalence of psoriasis varies from 0.44% to 2.8%, it is twice more 
common in males compared to females, and most of the patients are 
in their third or fourth decade at the time of presentation. There is a 
paucity of data related to Indian psoriasis patients on its genetics, 
epidemiology, pustular psoriasis, childhood psoriasis, disease severity, 
relapse, remission patterns and its associations [15].
Available treatment options for psoriasis are topical, oral systemic 
agents, phototherapy, and biologic therapy [5]. Traditional therapies 
such as methotrexate, cyclosporine A, retinoid therapy have a 
potential for long-term toxicity and not targeted against to root cause 
of psoriasis [1]. The main aim of a biologic is arresting the disease 
by specific targeting the immune or genetic mediator of pathogenic 
processes [16].
PSORIASIS TREATMENT BEFORE BIOLOGICAL
Traditionally, since biblical time’s patients with psoriasis treated 
with sun exposure and several clinical studies have strengthened 
this observation [17]. Moderate to severe psoriasis can be treated 
with conventional therapies like topical therapy, phototherapy and 
systemic therapy [18]. Broadly psoriasis treatment before biological 
is classified as a topical treatment, phototherapy, and non-biologic 
systemic therapy.
Topical treatment
Topical therapy is preferential treatment for mild psoriasis [19]. They 
can be used as adjuvant therapy to treat moderate to severe psoriasis. 
Emollients, dithranol, tar, deltanoids, vicorticoids, tacrolimus, anthralin, 
corticosteroids, salicylic acid, tars, tazarotene, vitamin D analogue 
(calcipotriene, calcitriol) are mostly used for topical treatment of 
psoriasis. Corticosteroids are mainstay in topical treatment especially 
for plaque psoriasis [18]. Betamethasone valerate, desonide, 
fluocinonide, hydrocortisone acetate, triamcinolone acetonide, 
clobetasol 17-propionate, halobetasol propionate are the few examples 
of frequently used topical corticosteroid. Corticosteroid act via a 
different mechanism like anti-proliferative, vasoconstrictive, apoptotic 
and anti-apoptotic action, immunosuppressive action. In rare cases, 
long-term widespread use of high-potency topical steroids is associated 
with suppression of the hypothalamic pituitary-adrenal axis [5,20]. 
Vitamin D analogues like calcipotriene, calitrol are also efficient options. 
Other topical treatments used are emollients/moisturizers, diathranol 
(anthralin), salicylic acid, calcineurien inhibitors, and retinoids [21-25]. 
Details of treatment option with their mechanism of action and adverse 
effect are explained in Table 1.
Phototherapy
Phototherapy has long been used for the treatment of skin 
conditions. Psoralen plus ultraviolet A (PUVA), broadband UVB 
(BB-UVB), and narrowband UVB (NB-UVB) form and excimer laser 
are available options of phototherapy. Phototherapy can be given 
either as monotherapy or in combination with topical or systemic 
agents. Wavelength between 311 and 313 nm was a most effective 
for treatment of psoriasis [18,26]. PUVA phototherapy consists of 
emission of UVA wavelengths (320-400 nm) after patients have 
ingested psoralen. NB-UVB has improved effectiveness over BB-UVB, 
and it is less erythemogenic has shorter clearing times and longer 
periods of remission. NB-UVB has also been confirmed to be similarly 
effective (in thin and medium plaque psoriasis), safer, and more 
practicable than PUVA. Nausea, headache, depression, hyperkinesis, 
and phototoxicity are common side effects while erythema and 
burning, premature aging of the skin, and presumed increase in 
skin cancer are the common risks of phototherapy. Phototherapy 
is contraindicated in patients with known lupus erythematosus or 
xeroderma pigmentosum. Combining phototherapy with topical 
vitamin D3 analogs may be of benefit by reducing the cumulative 
UV dose required for clearance of lesions and reducing the risk 
of cutaneous malignancy [27]. Lebwohl et al. in 2003 suggested 
Fig. 1: Pathogenesis of psoriasis
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application of vitamin D after phototherapy to avoid degradation of 
vitamin D [28]. Adachi et al. reported in 2008 topical application of 
vitamin D3 analogs either before or after irradiation by psoralen and 
UVA radiation (PUVA) or NB-UVB showed exactly similar effects in all 
patients [27].
Non-biologic systemic therapy
Methotrexate, cyclosporin, acitretin are most frequently used 
systemic therapy for psoriasis [29,30]. Drug, such as fumaric acid 
esters, mycophenolic mofetil, 6-thioguanine and hydroxyureas, is 
also used as non-biologic systemic therapy for treatment of psoriasis 
(Table 2) [31-33].
BIOLOGIC TREATMENT IN PSORIASIS
Biologic therapy contains protein biomolecules which are manufactured 
by living organisms. They have the aim to target specific points of 
inflammation cascade, including antibodies against cytokines, cell 
surface markers, and adhesion molecules [3]. The market available 
biologic for psoriasis treatment specifically targets T-cell, APCs and 
inflammatory mediator TNF-α. The introduction of biologic therapy 
has a great impression on psoriatic treatment duration and enhanced 
quality of life in psoriasis patients. They act as effective and safer 
substitute to traditional therapy as well as phototherapy for treatment 
of psoriasis [16].
Several biologic were approved for treatment of moderate to severe 




Secukinumab was first approved in Japan on December 26, 2014, for 
the treatment of psoriasis and psoriatic arthritis (PsA) in adults who 
are not sufficiently responding to systemic therapies (other than 
biologic therapy). It is a fully human monoclonal antibody against 
cytokine family member IL-17A, developed for the intravenous and 
subcutaneous route of administration. In early 2015, Secukinumab 
was approved by the USA and the EU, for the treatment of patients with 
moderate-to-severe plaque psoriasis. It is also under investigation for 
patients with ankylosing spondylitis and RA [34].
Mechanism of action
Secukinumab is a human monoclonal antibody which specifically binds 
and neutralizes the pro-inflammatory cytokine IL-17A. It neutralizes the 
activity of IL-17A but do not interfere with other functions of Th17 cells. 
In addition, it does not neutralize IL-17F. This new mechanism action 
results into the normalization of skin histology with almost clear 
skin in most of the patients [35]. IL-17 plays an important role in the 
pathogenesis of psoriasis which is produced by Th17 cells, neutrophils, 
mast cells, and T-cytotoxic 17 cells. IL-17 involved in host defense 
facilitated through certain mechanisms that include up-regulation 
of cytokine, chemokine, and antimicrobial peptide production [36]. 
IL-17A acts on keratinocytes to induce expression of chemokines 
required in recruiting myeloid DCs, Th17 cells, and neutrophils to the 
lesion site [37]. The increased level of Th17 cells in the circulation of 
psoriatic patient observed as compared to healthy subjects, and their 
level is strictly related to disease severity measured by psoriasis area 
and severity index (PASI) score [9].
Clinical trials
In four Phase III trials of secukinumab primary end point (at week 12) 
was measured ≥75% improvement in PASI 75 from baseline and a 
score of 0 (clear) or 1 (almost clear) on a 5-point Investigator’s Global 
Assessment scale (IGA mod 2011 0/1) versus placebo.
In the Phase III study (ERASURE), primary end point PASI 75 was 
attained at week 12 in 81.6% of the Psoriasis patients who received 
treatment 300 mg of secukinumab, 71.6% of those who received 
150 mg of the drug, and 4.5% of those in the placebo group (p<0.0001). 
IGA rates were 65.3% with 300 mg of secukinumab, 51.2% with 150 mg 
of secukinumab, and 2.4% with placebo [38]. Subsequent ERASURE 
study of secukinumab exhibited higher PASI 75 and IGA mod 2011 0/1 
responses in 300 mg (82.8% and 55.2%, respectively) or 150 mg (86.2% 
and 55.2%, respectively) versus placebo (6.9% and 3.4%, respectively). 
Secukinumab 300 mg dose was found more effective than 150 mg dose, 
in the maintenance period [39].
In the FIXTURE trial, PASI 75 was achieved by 77.1% (secukinumab 
300 mg) and 67% (secukinumab 150 mg); 44% (etanercept group) 
and 4.9% of patients in the placebo group. The IGA rates were 62.5% 
(300 mg of secukinumab), 51.1% (150 mg of secukinumab), 27.2% 
Table 1: Topical treatment for psoriasis
Topical treatment option Mechanism of action Adverse effect or limitation
Corticosteroid Antiproliferative, vasoconstrictive, apoptotic and 
anti-apoptotic action, immunosuppressive action
Epidermal atrophy, acneiform eruptions, allergic contact 
dermatitis, alopecia, myelosupression,
tachyphylaxis hypothalamic pituitary-adrenal axis suppression
Vitamin D analogues Normalization of keratinocyte hyperproliferation Irritant, hypercalcemia.
Short duration of remission necessitates constant treatment
Emollients/moisturizers Supportive role in normalizing 
hyperproliferation, differentiation, and 
apoptosis; anti-inflammatory effects
Some facial emollients may cause rashes, irritation
Diathranol (anthralin) Keratinocyte apoptosis Irritant to surrounding normal skin and may stain skin and clothing
Salicylic acid Keratolytic, reduces intercellular cohesion 
between corneocytes by dissolving the 
intercellular cement material and reducing the 
pH of the stratum corneum, thereby increasing 
hydration and softening
Oral pain, headache, central nervous system symptoms, dizziness, 
metabolic acidosis, tinnitus, nausea, vomiting and gastric 
symptoms, as well as hyperventilation.
Topical use of salicylic acid can reduce the efficacy of calcipotriol
Calcineurien inhibitors Inhibit calcineurin phosphatase activity and 
thereby inhibit activation of the transcription 
factor NFAT
Burning and itching. Should not be used with phototherapy or sun 
exposure
Retinoids Modulating the cellular differentiation of the 
epidermis, which results in decreased scaling,
erythema and thickness of the plaques
Slower onset of action, irritation, burning, itching, stinging, 
and erythema
Tazarotene is labeled as pregnancy category X and, therefore, 
it should not be used in women of childbearing age. Potentially 
photosensitizing so use with caution when combining with 
phototherapy
NFAT: Nuclear factor of activated T-cells
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Table 2: Non-biologic systemic therapy
Drug Mechanism of action Comments Side effects
Acitretin Retinoid regulates gene 
transcription by the action on 
nuclear receptor and reduces 
epidermal hyperplasia in 
psoriasis
•  First‑line systemic drug for chronic palmoplantar 
or pustular psoriasis in patients of non-child 
bearing potential
• Limited benefit for plaque psoriasis
Teratogenicity, hyperlipidemia, 
hepatotoxicity, alopecia, 
gastrointestinal, arthralgias and 
myalgias, pseudotumor cerebri, 
hyperostosis. Contraindicated in 
fertile female
Cyclosporine Immunosupressant •  Fast‑acting systemic drug that is often used 
first-line for von Zumbusch pustular psoriasis or 
erythrodermic psoriasis
•  For intermittent use in periods up to 12‑week as 
a short-term agent to control a flare of psoriasis
Renal toxicity, hypertension, 
gastrointestinal, flu-like 
symptoms, hypertrichosis, gingival 




Inhibitor of folate biosynthesis •  May be used as a first‑line systemic drug for 
plaque psoriasis
•  Compared to cyclosporine, has a more modest 
effect, but can be used continuously for years 
or decades
Hepatotoxicity, gastrointestinal, 
malaise, headache, reactivation of 
phototoxic reactions, ulcerative 
stomatitis, myelosuppression, 
anemia, pulmonary fibrosis, 
induction of lymphomas
Fumaric acid Inhibition of the expression of 
pro-inflammatory cytokines
• Mostly used for plaque‑type of psoriasis
•  If lymphocytes goes <500/µL or serum creatinine 
levels increase above the normal range the 
treatment should be stop
Gastrointestinal side effects and 
flushing of the skin. Contraindicated 
in chronic gastritis or active or 
recent gastric or duodenal ulcers. 
Patients suffering from severe liver 
or kidney diseases, patients under 
the age of 18 and women during 
pregnancy or lactation should also 
not be treated with FAEs
Mycophenolic 
mofetil
Immunosuppressive agent •  The frequency of malignant disorders is 
considerably higher than healthy control 
population
•  Mycophenolic acid can interact with antacids 
and cholestyramine and should not be used 
concomitantly
Gastrointestinal, leucopenia, higher 
incidence of herpes infection. 
Hematological side effect, hepatic 
and renal dysfunctions
Hydroxyurea Slows down the kinetics of basal 
cell replication in the epidermis, 
alters the red blood cell 
membrane and inhibits vascular 
proliferation in the dermis, lowers 
the neutrophil count in the skin, 
reverse the abnormal keratin 
proliferation in psoriatic plaques
•  Patients with severe psoriasis and pustular 
psoriasis achieved reasonable clinical clearance 
of their lesions
•  Contraindicated in patients with marked bone 
marrow depression or severe anemia.
Myelosuppression, 
hyperpigmentation, renal 
dysfunction, oral and leg ulcers, 
dermatomyositis-like skin changes
6-Thioguanine DNA de-arrangement •  Efficient in the treatment but leads to bone 
marrow toxicity
•  Hyperuricemia frequently occurs in patients 
receiving thioguanine as a result of rapid cell lysis
Bone marrow suppression 
(most patients at therapeutic 
doses exhibit some suppression), 
hepatotoxicity, hyperuricemia
FAE: Fumaric acid esters
Table 3: List of biologic approved for psoriasis treatment
Biologic Description Mechanism Status
Secukinumab 
(AIN457)
Human monoclonal antibody Anti-IL-17 Approved for psoriasis in 2015 (FDA)
Certolizumab Humanized monoclonal antibody TNF‑α inhibitor Approved for PsA in 2013 (FDA)
Itolizumab Humanized IgG1 monoclonal antibody Anti-CD6 T-cell Approved for psoriasis in 2013 (DCGI for India)
Golimumab Human monoclonal antibody TNF‑α inhibitor Approved for PsA in 2009 (FDA)
Ustekinumab Human monoclonal antibody IL-12/23 inhibitor Approved for psoriasis in 2009 (FDA)
Adalimumab Human monoclonal antibody TNF‑α inhibitor Approved for psoriasis in 2008 (FDA)
Infliximab Chimeric monoclonal antibody TNF‑α inhibitor Approved for psoriasis in 2006 (FDA)
Etanercept 1-235-TNF receptor (human) fusion protein with 
236‑467‑immunoglobulin G1 (human γ1‑chain 
Fc fragment), dimer
TNF‑α inhibitor Approved for psoriasis in 2004 (FDA)
Efalizumab Recombinant humanized monoclonal antibody LFA-1 inhibitor Approved for psoriasis in 2003 (FDA)
Alefacept 1-92-antigen LFA-3 (human) fusion protein with 




Approved for psoriasis in 2003 (FDA)
IL: Interleukin, LFA‑3: Lymphocyte function‑associated antigen 3, TNF‑α: Tumor necrosis factor‑alpha, IgG: Immunoglobulin G
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(etanercept), and 2.8% with placebo, respectively. The rates of infection 
were higher with secukinumab than with placebo in both ERASURE 
and FIXTURE studies and were similar to those with etanercept [38]. 
In another Phase III study, similar types of PASI 75 response and IGA 
score was reported when secukinumab was administered via pre-filled 
syringe (PFS) in subjects. PFS usability was high, all (100%) of subjects 
successfully self-administered treatment at week 1 [40].
In another study (JUNCTURE) secukinumab was administered via 
autoinjector/pen in moderate to severe plaque psoriasis patients. 
PASI 75 and IGA mod 2011 0/1 responses were superior with 
secukinumab 300 mg (86.7% and 73.3%, respectively) and 150 mg 
(71.7% and 53.3%, respectively) versus placebo (3.3% and 0%, 
respectively) (p<0.0001 for all). Patient acceptability of auto-injector 
was high throughout the period. Adverse events were observed as 
mild/moderate nasopharyngitis with secukinumab (300 mg, 70.0%; 
150 mg, 63.9%) versus placebo (54.1%) [41].
SCULPTURE study was planned to compare a fixed maintenance schedule 
of once-monthly dosing of secukinumab with dosing as needed to treat 
relapse. PASI 75 or greater response achieved patients on either 150 or 
300 mg of secukinumab were re-randomized at week 8 to receive either 
150 or 300 mg of secukinumab monthly injections or re-treatment as 
needed when relapse occurred. At week 52, 78% patients achieved 
PASI 75 responses who received 300 mg once monthly and did 68% 
of those in the as needed 300 mg drug group. PASI 75 was estimated 
in 62% patients who received 150 mg of secukinumab at 52 week 
with monthly dosing, while did 52% of those in the as-needed dosing 
group. PASI 90 responses were observed in 60% and 46% of patients 
who received 300 mg and 150 mg of secukinumab once monthly, at 
week 52 respectively. Considerably, lower PASI 90 score were detected 
for those patients who received either dose of secukinumab on an as 
needed basis [42].
Adverse events
Secukinumab treated psoriatic patients mainly susceptible for Candida 
infection; in addition, occurrence of adverse events, such as neutropenia, 




The U.S. Food and Drug Administration (FDA) approved CZP (Cimzia®) 
for use in the United States for the treatment of Crohn’s disease On 
April 22, 2008. European Medicines Agency first refused approval of 
CZP for the treatment of Crohn’s disease later on it was granted to UCB 
Pharma SA on October 1, 2009. FDA on May 13, 2009, approved it for 
RA afterward on September 27, 2013 it was approved for treatment 
of adult patients with active PsA later on October 18, 2013, it was 
approved in the treatment of ankylosing spondylitis. It was approved 
for axial spondyloarthritis in 39 countries [44-46].
Mechanism of action
CZP is a recombinant, humanized anti-TNF-α antigen binding 
fragment (Fab’) whose structure differs from other anti-TNF-α 
agents [47]. Overexpression of TNF-α is believed to play a key role 
in the pathogenic mechanisms linking psoriasis and arthritis. CZP 
selectively neutralizes TNF-α but does not neutralize lymphotoxin α 
(TNF-β). Incubation of monocytes with CZP caused a dose-dependent 
inhibition of lipopolysaccharide-induced TNF-α and IL1β production 
in human monocytes. It does not induce apoptosis in vitro in human 
peripheral blood-derived monocytes or lymphocytes, or neutrophil 
degranulation [46-48].
Clinical trials
In a Phase II trial, PASI 75 response was achieved by 75%, 83% and 7% 
patients with moderate-to-severe plaque psoriasis in the CZP 200 mg, 
CZP 400 mg and placebo groups, respectively. Similar results were 
observed in the re-treatment study conducted in PASI 75 responders in 
both CZP groups [49].
Two doses of CZP were compared with placebo in a Phase III study of 
PsA. ACR 20 response was significantly greater in CZP 200 mg every 
2 weeks (58.0%) and 400 mg every 4 weeks (51.9%) treated patients 
than placebo (24.3%) (p<0.001). Significant improvements observed 
by week 1 and maintained up to week 24. Moreover, CZP resulted in 
sustained improvements in psoriatic skin involvement, enthesitis, 
dactylitis and nail disease and quality of life [50].
Gladmen et al. examined the effect of CZP pegol on patient-reported 
outcomes in PsA patients with and without prior TNF inhibitor exposure. 
At week 24, significantly more CZP patients attained the minimum 
clinically important differences in pain, fatigue, physical function, and 
physical and mental component scores of the SF-36. The benefits of CZP 
treatment for health-related quality of life were seen across generic, 
PsA-specific and dermatology-specific measures and were observed in 
patients regardless of prior TNF inhibitor exposure [51].
Adverse events
Infections (respiratory tract, urinary tract, viral, etc.) are the most 
common side effect observed under CZP [49,50,52]. Other common 
side effects were fever, high blood pressure, rash or itching, headaches 
(including migraines), liver problems, injection site reactions, 
and sensory abnormalities such as numbness, tingling, burning 
sensation [46,49,50,52]. Increased risk of serious infections like 
tuberculosis, bacterial sepsis, invasive fungal infections (such as 
histoplasmosis) and infections due to other opportunistic pathogens 
may occur with CZP. Lymphoma and other malignancies have been 
reported in children and adolescent patients treated with TNF blockers, 
it is not indicated for use in pediatric patients [53].
Itolizumab
Regulatory status
Itolizumab is a humanized recombinant anti-CD6 monoclonal antibody, 
prepared by a T-cell epitope humanization approach from the murine 
clone ior t1 [54,55]. Itolizumab (alzumab) was approved in January 
2013 for the treatment of chronic plaque psoriasis by the Drugs 
Controller General of India [56]. It is also approved in Cuba for the 
treatment of moderate to severe plaque psoriasis [54].
Mechanism of action
Itolizumab targets CD6, which is predominantly expressed by T-cells 
and a subset of B-cells [57]. It inhibits CD6-mediated co-stimulation of 
T-cells and down-regulates production of multiple pro-inflammatory 
Table 4: Biologics in clinical trials
Biologic Description Mechanism Status
Ixekizumab (LY2439821) Humanized monoclonal antibody Anti-Th17 Phase III completed
Briakinumab Human monoclonal antibody IL-12/23 p40 inhibitor Phase III completed 
Brodalumab (AMG827) Human monoclonal antibody Anti-IL-17 Phase III ongoing
Guselkumab (CNTO1959) Human monoclonal antibody Anti-IL23p19 Phase III ongoing 
Tildrakizumab (MK3222/SCH-900222) Humanized monoclonal antibody Anti-IL-23 Phase III ongoing
Tregalizumab (BT-061) Humanized anti-CD4 monoclonal antibody T-regulatory cell activator Phase IIA completed
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cytokines. The effect is achieved by influencing mitogen-activated 
protein kinase and a signal transducer, in addition, activator of 
transcription-3 signaling pathways which lead to a reduction in 
production of pro-inflammatory cytokines such as IFN-γ, IL-6 and 
TNF. T-cells in circulation are not reduced so general immunity is not 
compromised [56,58].
Clinical trial
In a Phase II trial, itolizumab exhibited consistent reduction in PASI 
score from baseline visit to week 12. Itolizumab showed prompt 
PASI 75 response in 42.5 % patients at week 8 while 45 % in patients 
at week 12 [58]. Krupashankar et al. reported that itolizumab was 
effective and well tolerated in chronic plaque psoriasis patient. At week 
12, significant PASI 75 response was achieved in 27.0% and 36.4% in 
two regimens of itolizumab as compared to 2.3% in placebo-treated 
patients. At week 28, the PASI 75 score was comparable for placebo and 
itolizumab treated patients [59].
Adverse events
Diarrhea, infusion-related reactions, upper respiratory tract infection 
and pruritic were the most common side effects reported [58,59].
Ustekinumab
Regulatory status
In 2009, FDA was the first approved Ustekinumab (Stelara) for 
adults who have a moderate to severe form of psoriasis. Further, it 
was approved for PsA in 2013. Ustekinumab is a human monoclonal 
antibody that targets IL-12/23 p40 to treat psoriasis. It is administered 
as a subcutaneous injection [60].
Mechanism of action
Ustekinumab is the first of a new class of biological drugs that 
specifically binds to common p40 protein subunit of human cytokines 
IL-12 and IL-23. It inhibits the activity of human IL-12 and IL-23 by 
averting p40 subunit interaction with IL-12Rβ1 receptor protein 
expressed on the surface of immune cells. IL-12 and IL-23 are cytokines 
secreted by activated macrophages or DCs. These cytokines involved 
in activation of NK-cells and CD4+ T-cell differentiation as well as 
activation. Thus, it targets both Th1 and Th17 arms of immunity [61]. 
IL-23 stimulates proliferation of Th17 cells, these cells regulate the 
production of inflammatory cytokines (IL-17, IL-22, IL-21, IL-6, TNF-α 
which are predominantly observed in psoriatic plaques [62]. Th1 cell 
express the transcription growth factor-β after exposure to IL-12 as 
well as produces pro-inflammatory cytokines (IFN-γ, TNF-α, IL-2) [63].
Clinical trials
PHOENIX (1 and 2), and ACCEPT studies proved beneficial in patients 
who were less responsive to immunosuppressive treatment including 
cyclosporine or methotrexate, phototherapy and unable to use or 
tolerate other therapies [62].
In PHOENIX 1 trial, PASI 75 score was found equal (67.1%) in both 
ustekinumab 45 mg and 90 mg groups than the placebo group (3.1%); 
(p<0.0001) [64]. While in PHOENIX 2 trial significantly more patients 
achieved a PASI 75 response at week 12 on ustekinumab 45 mg (66.7%) 
or 90 mg (75.7%) than on placebo (3.7%); (p<0.0001) [65]. Griffiths 
et al. reported similar results as in PHOENIX 2 trials with additional 
arm of etanercept 50 mg, who achieved PASI 75 score 56.8%. Both 
dose of ustekinumab found superior than etanercept (p=0.01) and 
injection-site reactions were significantly more commonly observed 
with etanercept-treated patients than on ustekinumab [66]. In a 
PSUMMIT 1 trial, both doses of ustekinumab found effective in PsA 
patients and achieved ACR20 score 42.4% (45 mg), 49.5% (90 mg) in 
ustekinumab-treated patients than placebo-treated (22·8%) patients 
(p<0.0001) [67].
Adverse events
The adverse events were generally mild. The most commonly 
reported were a headache, cough, nasopharyngitis, injection site 
erythema, upper respiratory tract infections, and arthralgia [64-66]. 




Adalimumab is a human monoclonal antibody against TNF-α. It is 
produced by recombinant DNA technology using a mammalian cell 
expression system [68].
U.S. FDA approved adalimumab to treat RA in 2002, PsA in 2005, 
ankylosing spondylitis in 2006, Crohn’s disease in 2007, plaque 
psoriasis in 2008, juvenile idiopathic arthritis in 2008, ulcerative colitis 
in 2012 and pediatric patients with Crohn’s Disease in 2014 [69].
Mechanism of action
Adalimumab acts by prevention of the interaction of TNF-α with the 
p55 and p75 cell surface TNF receptors [70]. Adalimumab causes 
inhibition of release of serum cytokines (IL-6), acute phase reactants of 
inflammation, matrix metalloproteases, and other markers of cartilage 
and synovium turnover. It also modulates biological response level of 
adhesion molecules like endothelial leukocyte adhesion molecule 1, 
vascular cell adhesion molecule 1, ICAM-1 responsible for leukocyte 
migration [70,71].
Clinical trial
In a Phase II study, adalimumab exhibited statistically significant 
improvement in mean PASI score from week 1. Further, it achieved PASI 
75 response in 53% of patients (40 mg every other week) and 80% of 
patients (40 mg/week) as compared to 4% of patients treated with 
placebo. The response to adalimumab was continued over week 60 in 
the majority of patients without any major side effects [72].
Adalimumab proved radical improvement in psoriasis patients 
compared with methotrexate and with placebo in CHAMPION trial (16-
week study). The complete clearance of disease was observed in 16.7%, 
7.3% and 1.9% patients treated with adalimumab, methotrexate and 
placebo-treated patients respectively. The occurrences of adverse 
events were similar in treatment groups [73,74].
Sub analysis of CHAMPION study suggests that week 12 may be an 
ideal time to decide whether a patient should continue methotrexate 
or switch to a different therapy because patients who achieved PASI 75 
responses after 16 weeks of treatment with methotrexate in CHAMPION 
study had achieved a PASI 50 response by week 12, and did so with 
dosages not exceeding 20 mg per week [75]. In another Phase III trial, 
71% of adalimumab and 7% of placebo-treated patients achieved 
greater than or equal to 75% improvement in the PASI score at week 
16. Limitation of this study was the absence of an active comparator 
and evaluation of maintenance of response beyond week 52 [76].
Adverse events
Upper respiratory infections, nasopharyngitis, headache, fungal 
infections and injection site reactions were the most common side 
effects observed [70,71,76,77].
CONCLUSION
Psoriasis is now become common disease that can have a significant 
impact on the quality of life. The enhanced courtesy on the development 
of new biologic therapy has made a revolution in psoriasis treatment. 
Many treatment options such as topical, phototherapy and systemic 
are available for the treatment of psoriasis but long-term use of these 
therapies are associated with cumulative toxicity. Recent advances in 
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the understanding of the pathogenesis of psoriasis have agreed for the 
identification of more selective targets. Currently approved biologic 
for psoriasis treatment are adalimumab, infliximab, etanercept, 
ustekinumab, alefacept, and secukinumab. Long-term side effects and 
efficacy will become beneficial to determine which one is a best suitable 
candidate for long-term care of psoriasis.
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